WuXi AppTec Co Ltd
SSE:603259
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (14.5), the stock would be worth ¥94.56 (6% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.4 | ¥100.19 |
0%
|
| 3-Year Average | 14.5 | ¥94.56 |
-6%
|
| 5-Year Average | 17.6 | ¥114.55 |
+14%
|
| Industry Average | 20.1 | ¥130.54 |
+30%
|
| Country Average | 20.8 | ¥135.43 |
+35%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 15.4 | 15.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 774.1 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
175.6B USD | 25.5 | 26.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.4B USD | 21.5 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 31.3 | -119.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.3B USD | 24.3 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD | 47.3 | 47.5 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.3B USD | 14.7 | 20.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 29 | 29.6 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
15.4B EUR | 24.7 | 58.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
WuXi AppTec Co Ltd
Glance View
In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.